ABRYSVO® Dosage and Administration

(Respiratory Syncytial Virus Vaccine)

2 DOSAGE AND ADMINISTRATION

2.1 Dose and Schedule

After reconstitution, a single dose of ABRYSVO is either 0.5 mL (Act-O-Vial presentation and vial and vial presentation) or approximately 0.5 mL (vial and prefilled syringe presentation) [see Dosage and Administration (2.2)].

2.2 Presentations and Reconstitution

ABRYSVO is supplied in 3 presentations as follows:

Act-O-Vial Presentation

The Act-O-Vial presentation is supplied in cartons. Each Act-O-Vial contains the Lyophilized Antigen Component (a sterile white powder) and Sterile Water Diluent Component.

Vial and Prefilled Syringe Presentation

The vial and prefilled syringe presentation is supplied in cartons containing a kit(s). Each kit includes a vial of Lyophilized Antigen Component (a sterile white powder), a prefilled syringe containing Sterile Water Diluent Component, and a vial adapter.

Vial and Vial Presentation

The vial and vial presentation is supplied in cartons that include vials of Lyophilized Antigen Component (a sterile white powder) and vials containing Sterile Water Diluent Component.

For all presentations, reconstitute the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO, as described in the instructions below.

Reconstitution Instructions for the Act-O-Vial Presentation

AoVAoV_Step1AoV_Step2

Act-O-Vial presentation

Step 1. Reconstitution of the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO

Place the Act-O-Vial on a flat surface and firmly press down on the plastic activator cap to release the center stopper and Sterile Water Diluent Component into the lower chamber.

Gently swirl the Act-O-Vial until the powder is completely dissolved.

Do not shake.

Step 2. Withdrawal of ABRYSVO

Remove the plastic tab covering the center of the top stopper.

Using a sterile needle and syringe, insert the needle straight through the center of the stopper.

Invert the Act-O-Vial and withdraw 0.5 mL of ABRYSVO.

Discard the Act-O-Vial and excess volume after withdrawal of a single dose.

Reconstitution Instructions for Vial and Prefilled Syringe Presentation

Step1-VPStep 2-VPStep 3-VPStep 4-VP

Step 1. Attachment of the vial adapter to the vial

Remove the flip top cap from the vial of Lyophilized Antigen Component.

Peel off the top cover from the vial adapter packaging.

While keeping the vial adapter in its packaging, center the adapter over the vial’s stopper and attach to the vial with a straight downward push.

Remove the packaging.

Step 2. Connection of the syringe to the vial adapter

Hold the syringe of Sterile Water Diluent Component by the Luer lock adapter.

Twist to remove the syringe cap.

Connect the syringe to the vial adapter by turning the Luer lock.

Step 3. Reconstitution of the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO

Inject the entire contents of the syringe into the vial.

Hold the plunger rod down and gently swirl the vial until the powder is completely dissolved.

Do not shake.

Step 4. Withdrawal of ABRYSVO

Invert the vial completely and slowly withdraw the entire contents into the syringe for an approximately 0.5 mL dose of ABRYSVO.

Twist to disconnect the syringe from the vial adapter.

Attach a sterile needle suitable for intramuscular injection.

Reconstitution Instructions for the Vial and Vial Presentation

Step 1-VVStep 2a-VVStep 2b-VVStep 3-VV

Step 1. Withdrawal of the Sterile Water Diluent

Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the Sterile Water Diluent Component.

Step 2. Reconstitution of the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO

Inject the entire contents into the vial containing the Lyophilized Antigen Component (white powder). Gently swirl the vial in a circular motion until the powder is completely dissolved. Do not shake.

Step 3. Withdrawal of ABRYSVO

Withdraw 0.5 mL from the vial containing the reconstituted vaccine.

Discard the vial and any excess volume after withdrawal of a single dose.

2.3 Administration

For intramuscular injection

After reconstitution, ABRYSVO is a clear and colorless solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if either condition is present.

Administer ABRYSVO immediately or store at room temperature [15°C to 30°C (59°F to 86°F)] and use within 4 hours. Discard reconstituted vaccine if not used within 4 hours.

Find ABRYSVO® medical information:

Find ABRYSVO® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ABRYSVO® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Dosage and Administration

2 DOSAGE AND ADMINISTRATION

2.1 Dose and Schedule

After reconstitution, a single dose of ABRYSVO is either 0.5 mL (Act-O-Vial presentation and vial and vial presentation) or approximately 0.5 mL (vial and prefilled syringe presentation) [see Dosage and Administration (2.2)].

2.2 Presentations and Reconstitution

ABRYSVO is supplied in 3 presentations as follows:

Act-O-Vial Presentation

The Act-O-Vial presentation is supplied in cartons. Each Act-O-Vial contains the Lyophilized Antigen Component (a sterile white powder) and Sterile Water Diluent Component.

Vial and Prefilled Syringe Presentation

The vial and prefilled syringe presentation is supplied in cartons containing a kit(s). Each kit includes a vial of Lyophilized Antigen Component (a sterile white powder), a prefilled syringe containing Sterile Water Diluent Component, and a vial adapter.

Vial and Vial Presentation

The vial and vial presentation is supplied in cartons that include vials of Lyophilized Antigen Component (a sterile white powder) and vials containing Sterile Water Diluent Component.

For all presentations, reconstitute the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO, as described in the instructions below.

Reconstitution Instructions for the Act-O-Vial Presentation

AoVAoV_Step1AoV_Step2

Act-O-Vial presentation

Step 1. Reconstitution of the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO

Place the Act-O-Vial on a flat surface and firmly press down on the plastic activator cap to release the center stopper and Sterile Water Diluent Component into the lower chamber.

Gently swirl the Act-O-Vial until the powder is completely dissolved.

Do not shake.

Step 2. Withdrawal of ABRYSVO

Remove the plastic tab covering the center of the top stopper.

Using a sterile needle and syringe, insert the needle straight through the center of the stopper.

Invert the Act-O-Vial and withdraw 0.5 mL of ABRYSVO.

Discard the Act-O-Vial and excess volume after withdrawal of a single dose.

Reconstitution Instructions for Vial and Prefilled Syringe Presentation

Step1-VPStep 2-VPStep 3-VPStep 4-VP

Step 1. Attachment of the vial adapter to the vial

Remove the flip top cap from the vial of Lyophilized Antigen Component.

Peel off the top cover from the vial adapter packaging.

While keeping the vial adapter in its packaging, center the adapter over the vial’s stopper and attach to the vial with a straight downward push.

Remove the packaging.

Step 2. Connection of the syringe to the vial adapter

Hold the syringe of Sterile Water Diluent Component by the Luer lock adapter.

Twist to remove the syringe cap.

Connect the syringe to the vial adapter by turning the Luer lock.

Step 3. Reconstitution of the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO

Inject the entire contents of the syringe into the vial.

Hold the plunger rod down and gently swirl the vial until the powder is completely dissolved.

Do not shake.

Step 4. Withdrawal of ABRYSVO

Invert the vial completely and slowly withdraw the entire contents into the syringe for an approximately 0.5 mL dose of ABRYSVO.

Twist to disconnect the syringe from the vial adapter.

Attach a sterile needle suitable for intramuscular injection.

Reconstitution Instructions for the Vial and Vial Presentation

Step 1-VVStep 2a-VVStep 2b-VVStep 3-VV

Step 1. Withdrawal of the Sterile Water Diluent

Using a sterile needle and sterile syringe, withdraw the entire contents of the vial containing the Sterile Water Diluent Component.

Step 2. Reconstitution of the Lyophilized Antigen Component with the Sterile Water Diluent Component to form ABRYSVO

Inject the entire contents into the vial containing the Lyophilized Antigen Component (white powder). Gently swirl the vial in a circular motion until the powder is completely dissolved. Do not shake.

Step 3. Withdrawal of ABRYSVO

Withdraw 0.5 mL from the vial containing the reconstituted vaccine.

Discard the vial and any excess volume after withdrawal of a single dose.

2.3 Administration

For intramuscular injection

After reconstitution, ABRYSVO is a clear and colorless solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if either condition is present.

Administer ABRYSVO immediately or store at room temperature [15°C to 30°C (59°F to 86°F)] and use within 4 hours. Discard reconstituted vaccine if not used within 4 hours.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.